<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="../../web/xslt/drug-table.xslt"?><drug name = "dexrazoxane inj VIAL>
<dose><value>500</value>
<value>1000</value>
</dose><route><value>IV</value>
</route><form><value>inj VIAL</value>
</form><drug><value>dexrazoxane inj VIAL</value>
</drug><strength><value>250 mg</value>
<value>500 mg</value>
</strength><frequency><value>ONCE</value>
<value>Q24H  </value>
</frequency><instruction><value></value>
<value>for 2 days. Administer dose over 1 to 2 hours. </value>
<value>Administer on third day off 3day protocol. Administer dose over 1 to 2 hours.</value>
</instruction><volume><value></value>
</volume><units><value>mg/m2</value>
</units><additionalnotes><value>10:1 dosing ratio for use with DOXOrubicin as a cardioprotectant. Maintain 10:1 dosing ratio where DOXOrubicin dose is decreased. Recoomend reducing dose by 50% in patients with CrCl less than 40 mL/minute.</value>
<value>10:1 dosing ratio for use with epirubicin as a cardioprotectant. Maintain 10:1 dosing ratio when epirubicin dose is decreased. Recommend reducing dose 50% in patients with CrCl less than 40 mL/minute.</value>
<value>Extravasation Treatment. 3 day protocol. First dose should be initiated as soon as possible (within the first 6 hours after extravasation) with subsequent doses 24 hours apart. MAXIMUM dose (DAY 1 &amp; 2): 2000 mg/day. Recommend reducing dose 50% in patients with CrCl less than 40 mL/minute.</value>
<value>Extravasation Treatment. 3 day protocol. First dose should be initiated as soon as possible (within the first 6 hours after extravasation) with subsequent doses 24 hours apart. MAXIMUM dose (DAY 3): 1000 mg/day. Recommend reducing dose 50% in patients with CrCl less and 40 mL/minute.</value>
</additionalnotes><population><value>ADULT</value>
</population><indicationprn><value></value>
</indicationprn><backgroundinformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3583</value>
<value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3584</value>
</backgroundinformation><prninformation><value></value>
</prninformation><ahsformularystatus><value>Formulary with Restrictions.</value>
</ahsformularystatus><ahfsname><value>Protective Agents</value>
</ahfsname><highalert><value></value>
</highalert><maximumprndose><value></value>
</maximumprndose></drug>